Introduction:

diabetic foot ulcer is a health problem which requires effective treatment to decrease the rate of amputations.

Objective:

to evaluate the therapeutic effectiveness of Heberprot-P® (recombinant human epidermal growth factor), applied to diabetic foot ulcer patients.

Methods:

non-randomized, uncontrolled trial in 51 diabetic foot patients treated with Heberprot-P® at General Teaching Hospital of Chimborazo, Riobamba, Ecuador, during the period from January to December 2013. The variables analyzed were: age, sex, type of diabetes, place of origin, clinical classification of disease, injury classification, number of infiltrations carried out, treatment time, response to it and adverse events.

Results:

the most predisposed to diabetic foot ulcers was the 60-70 age group and the female. 58.8% of the patients presented neuroinfectious diabetic foot. According to Wagner classification, in Grade II injury, the most frequent, after 24 infiltrations of Herberprot P®, the response to the treatment observed was total healing in 70.5% and partial in 27.5%, being satisfactory in 98% of the patients within a period of 50 days. The main adverse effect found was chills.

Conclusions:

the effectiveness of Heberprot-P® in the treatment of diabetic foot ulcer patients is confirmed, in addition to being an effective and safe drug for application.

        · resumen en Español     · texto en Español     · Español ( pdf )